Announcement on behalf of OBIGEN that it has filed the application of repeat-dose Phase II safety study for OBI-858 to TFDA

Date of occurrence of the event:2024/11/26 New drug name or code:OBI-858 Novel Botulinum Neurotoxin Indication: OBI-858, an in-house developed novel botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic uses. Patents for its special molecular weight have been granted in Taiwan, Australia, New Zealand, Japan and Russia. Clinical trial information: https://www1.cde.org.tw/ct_taiwan/search_case2.php?caseno_ind%5B1%5D=17596 Planned development stages: […]